CLINICAL TRIALS PROFILE FOR ICOTROKINRA HYDROCHLORIDE

All Clinical Trials for ICOTROKINRA HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06807424 ↗	A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis	RECRUITING	Janssen Research & Development, LLC	PHASE3	2025-01-09	The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
NCT06878404 ↗	A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-nave Participants With Active Psoriatic Arthritis	RECRUITING	Janssen Research & Development, LLC	PHASE3	2025-02-21	The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
NCT07196722 ↗	A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease	RECRUITING	Janssen Research & Development, LLC	PHASE2	2025-10-03	The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

Clinical Trial Conditions for ICOTROKINRA HYDROCHLORIDE

Condition Name

Condition Name for ICOTROKINRA HYDROCHLORIDE
Intervention	Trials
Arthritis, Psoriatic	2
Colitis, Ulcerative	1
Crohn Disease	1

Condition MeSH

Condition MeSH for ICOTROKINRA HYDROCHLORIDE
Intervention	Trials
Arthritis, Psoriatic	2
Crohn Disease	1
Colitis, Ulcerative	1

Clinical Trial Locations for ICOTROKINRA HYDROCHLORIDE

Trials by Country

Trials by Country for ICOTROKINRA HYDROCHLORIDE
Location	Trials
United States	33
Japan	4
Canada	3
Germany	2
India	2

Trials by US State

Trials by US State for ICOTROKINRA HYDROCHLORIDE
Location	Trials
Texas	4
Pennsylvania	4
Illinois	2
Florida	2
Arkansas	2

Clinical Trial Progress for ICOTROKINRA HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ICOTROKINRA HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE3	3
PHASE2	1

Clinical Trial Status

Clinical Trial Status for ICOTROKINRA HYDROCHLORIDE
Clinical Trial Phase	Trials
RECRUITING	4

Clinical Trial Sponsors for ICOTROKINRA HYDROCHLORIDE

Sponsor Name

Sponsor Name for ICOTROKINRA HYDROCHLORIDE
Sponsor	Trials
Janssen Research & Development, LLC	4

Sponsor Type

Sponsor Type for ICOTROKINRA HYDROCHLORIDE
Sponsor	Trials
INDUSTRY	4

Last updated: May 2, 2026

ICOTROKINRA HYDROCHLORIDE: Clinical Trial Update, Market Analysis, and 3–7 Year Projections

ICOTROKINRA HYDROCHLORIDE has insufficient publicly verifiable clinical-development and commercialization data to produce a complete clinical trials update or a defensible market projection. No complete, citable record is available in the public domain for trial phase, indications, enrollment status, endpoints, safety/efficacy readouts, regulatory filings, or launch plans under this exact drug name.

The result: any attempt to quantify clinical status or revenue potential would require data that is not present in the accessible record for this specific asset name.

What is the publicly verifiable clinical-trial status for ICOTROKINRA HYDROCHLORIDE?

No citable evidence is available here to support:

• Trial identifier(s) (e.g., NCT/EudraCT) tied to the exact drug name
• Indication(s), phase, enrollment, or sites
• Interim or final readouts (primary endpoint results)
• Safety signals (SAE rates, discontinuations, immunogenicity)
• Top-line summaries from registries or sponsor releases

What is the publicly verifiable regulatory position for ICOTROKINRA HYDROCHLORIDE?

No citable evidence is available here to support:

• Agency interactions (e.g., FDA Breakthrough/Orphan, SPA status, End-of-Phase 2 meetings)
• IND/NDA/MAA filings or review milestones
• Granted approvals in any jurisdiction
• Label scope, contraindications, boxed warnings, or REMS obligations

What is the addressable market and competitive positioning for ICOTROKINRA HYDROCHLORIDE?

No citable evidence is available here to support:

• Target indication and mechanism of action (required to define TAM/SAM/SOM)
• Competitive set (approved drugs, late-stage assets, biologics/chemotherapies/DMARDs, etc.)
• Pricing benchmarks (WAC, negotiated discounts)
• Evidence of clinical adoption, formulary placement, or utilization

Can ICOTROKINRA HYDROCHLORIDE be projected to a revenue outcome?

Not on a defensible basis, because all required inputs for a revenue model are missing for this exact asset name:

• Indication and patient population
• Clinical outcome and probability-adjusted adoption
• Regulatory probability and timing
• Pricing and payer dynamics by country/segment
• Launch timing, geography, and channel strategy

---

Key Takeaways

• A complete, citable clinical trials update cannot be produced for ICOTROKINRA HYDROCHLORIDE under its exact name.
• A defensible market analysis and 3–7 year revenue projection cannot be produced without indication, trial outcomes, and regulatory/launch data that are not available here.
• Any quantified projection or competitive landscape would be non-actionable due to missing primary inputs.

---

FAQs

1. Is ICOTROKINRA HYDROCHLORIDE approved anywhere?
   No citable approval record is available here for the exact drug name.

2. What phase are its clinical trials in?
   No citable trial registry record is available here tied to the exact name.

3. What indication does ICOTROKINRA HYDROCHLORIDE target?
   No citable indication mapping is available here for the exact drug name.

4. What companies are developing ICOTROKINRA HYDROCHLORIDE?
   No citable sponsor/developer information is available here for the exact drug name.

5. How can a revenue projection be built for this asset?
   A projection requires indication, mechanism, clinical outcomes, regulatory milestones, pricing, and geography, none of which are citable here for this exact name.

---

References

1. None (no citable sources for ICOTROKINRA HYDROCHLORIDE clinical trials, regulatory status, or market-relevant details were provided or verifiable in the accessible record for this exact drug name).